All In Biotech

Drug Trial Radar · NCT01052597

Curcumin for Type 2 Diabetic Patients

Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients

Last checked: Nov 20, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 2009

Primary completion

Feb 2010

Study completion Mar 2010

Sponsor

Lead sponsor
Srinakharinwirot UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Thailand
First posted
Jan 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.

Conditions

  • Type 2 Diabetes Mellitus
  • Cardiovascular Abnormalities

Interventions

  • curcuminDrug

    Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patientsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HRH Princess Maha Chakri Sirindhorn Medical Center

    Ongkarak, Nakornnayok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.